Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ("Tanabe Pharma", "MTPC" or "the Company") ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

Bain Capital is nearing a deal to buy Mitsubishi Chemical Group Corp.’s pharmaceutical unit, people familiar with the matter ...

Mitsubishi Chemical, a Japanese corporation has agreed to sell its pharmaceutical subsidiary, Tanabe Mitsubishi Pharma, to U.S. private equity firm Bain Capital, according to Reuters on Friday.

Significantly increased risk for tardive dyskinesia seen with doses >75 mg/day at last prescription and as maximum dose.

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Find out more at www.lonza.com Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world ...

Significantly increased risk for tardive dyskinesia seen with doses >75 mg/day at last prescription and as maximum dose ...